Figure 7.

Demonstration in two additional CD8⁺ CTL clones of nifidipene inhibition of perforin cytolysis and thapsigargin induction of cytolysis that is inhibited by anti-FasL. Clone 11-1 (a) and 14-13 (b) were pretreated for 40 min with nifedipine at various concentrations before the start of a ⁵¹Cr–release assay. The CTLs were incubated with 0.10 μM HA204–212 (a) or 0.01 μM nucleoprotein 147–155 (b) peptide–pulsed L1210Fas⁻ targets (▪) or L1210Fas⁺ targets (•) in a ⁵¹Cr–release assay (a and b). Clones 11-1(▪) and 14-13(•) were stimulated with PMA (25 ng/ ml) plus different doses of ionomycin (c) or thapsigargin (d) and granzyme A granule exocytosis was determined. Clones 11-1(▪) and 14-13(•) were stimulated with 200, 20, or 2 nM of ionomycin (e) or thapsigargin (f) and percentage of specific ⁵¹Cr–release of the L1210Fas⁺ target determined in the absence (▪, •) or presence (□, ○) of anti-FasL antibody.